Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:46:57.226Z.
Calculation as of: 2026-10-06T14:46:57.226Z.
Quote observation: 2026-10-06T14:45:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5aadd97284981d173c87413c67de95801d58f7ce8cc73935cbfc70b12a62615a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Generate Biomedicines, Inc.
Market Cap
$1.75B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.73B
EV/EBITDA Ratio
4.45x
TTM Avg
6.94x
3Y Avg
36.47x
5Y Avg
27.65x
Market Cap
$1.72B
EV/EBITDA Ratio
15.73x
TTM Avg
130.62x
3Y Avg
220.82x
5Y Avg
220.82x
Market Cap
$1.71B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.81B
EV/EBITDA Ratio
N/A
TTM Avg
2603.44x
3Y Avg
1662.57x
5Y Avg
1662.57x
Market Cap
$1.82B
EV/EBITDA Ratio
21.88x
TTM Avg
30.23x
3Y Avg
32.57x
5Y Avg
30.28x
Market Cap
$1.84B
EV/EBITDA Ratio
13.52x
TTM Avg
17.09x
3Y Avg
17.06x
5Y Avg
16.05x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.75B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 4.45x | 6.94x | 36.47x | 27.65x |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.72B | 15.73x | 130.62x | 220.82x | 220.82x |
| Absci Corporation (ABSI)vs › | $1.79B | N/A | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | N/A | N/A | N/A | N/A |
| Novocure Ltd (NVCR)vs › | $1.81B | N/A | 2603.44x | 1662.57x | 1662.57x |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 21.88x | 30.23x | 32.57x | 30.28x |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | 13.52x | 17.09x | 17.06x | 16.05x |
| Novavax, Inc. (NVAX)vs › | $1.85B | N/A | 3.29x | 3.29x | 3.29x |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.86B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
